SUTRO BIOPHARMA, INC. Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SUTRO BIOPHARMA, INC. stock issued during period, value, restricted stock award, net of forfeitures for the quarter ending 2025-06-30 was $1.00K.
- SUTRO BIOPHARMA, INC. stock issued during period, value, restricted stock award, net of forfeitures for the quarter ending 2023-09-30 was $1.00K.
- SUTRO BIOPHARMA, INC. stock issued during period, value, restricted stock award, net of forfeitures for fiscal 2025 was $1.00K.
- SUTRO BIOPHARMA, INC. stock issued during period, value, restricted stock award, net of forfeitures for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- SUTRO BIOPHARMA, INC. stock issued during period, value, restricted stock award, net of forfeitures for fiscal 2023 was $1.00K.
| Period end | Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures 3 month | Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures 12 month |
|---|---|---|
| 2025-12-31 | $1.00K 10-K · filed 2026-03-23 | |
| 2025-06-30 | $1.00K 10-Q · filed 2026-08-12 | |
| 2024-12-31 | $0.00 10-K · filed 2026-03-23 | |
| 2023-12-31 | $1.00K 10-K · filed 2025-03-13 | |
| 2023-09-30 | $1.00K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |